FDA approves Nulojix for kidney transplant patients

Posted by Food and Drug Administration--Press Releases on Wednesday Jun 15, 2011 Under News

The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant. The drug is approved for use with other immunosuppressants (medications that suppress the immune system) — specifically basiliximab, mycophenolate mofetil, and corticosteroids.

Be Sociable, Share!

Comments are closed.